MedTrace Logo

A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2

NCT05113862 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-02-12

No results posted yet for this study

Summary

This trial is Stage 2 of a 2-part adaptive trial. The study aims to investigate the safety of 2 doses of a T-cell priming specific cocktail of Coronaviruses peptides mounted on a gold nanoparticle.

Note: Stage 1 of the 2-part adaptive trial, testing a specifically selected mix of Dengue virus peptides, commenced Aug 2021. This is now in follow up (NCT04935801).

Conditions

Interventions

BIOLOGICAL

LD Vehicle-GNP

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

LD PepGNP-Covid19

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

HD Vehicle-GNP

Two intradermal injections in the upper arm spaced 21 days apart

BIOLOGICAL

HD PepGNP-Covid19

Two intradermal injections in the upper arm spaced 21 days apart

Sponsors & Collaborators

  • Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

    collaborator OTHER

  • University of Lausanne Hospitals

    collaborator OTHER

  • Gylden Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Blaise Genton, Prof. · Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2022-09-15
Completion
2022-09-15

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05113862 on ClinicalTrials.gov